Differences in emergency endoscopy outcomes according to gastrointestinal bleeding location.

AIMS65 score Glasgow–Blatchford score NOBLADS score Upper gastrointestinal bleeding clinical course lower gastrointestinal bleeding prognostic factors

Journal

Scandinavian journal of gastroenterology
ISSN: 1502-7708
Titre abrégé: Scand J Gastroenterol
Pays: England
ID NLM: 0060105

Informations de publication

Date de publication:
Jan 2021
Historique:
pubmed: 18 11 2020
medline: 19 8 2021
entrez: 17 11 2020
Statut: ppublish

Résumé

With recent technological advances in the field of endoscopic hemostasis, the prognosis of patients with gastrointestinal (GI) bleeding has improved. However, few studies have reported on the clinical course of patients with GI bleeding. This study aimed to evaluate the differences in clinical outcomes of patients with lower GI bleeding (LGIB) compared with upper GI bleeding (UGIB) and the factors related to their prognosis. Patients who had undergone emergency endoscopy for GI bleeding were retrospectively reviewed. The severity of GI bleeding was evaluated using the Glasgow-Blatchford (GB), AIMS65, and NOBLADS scores. Patients in whom obvious GI bleeding relapsed and/or iron deficiency anemia persisted after emergency endoscopy were considered to exhibit rebleeding. We reviewed 1697 consecutive patients and divided them into UGIB (1054 patients) and LGIB (643 patients) groups. The proportion of patients with rebleeding was significantly greater in the UGIB group than in the LGIB group; the mortality rate was significantly higher in the UGIB group than in the LGIB group. Multivariate analysis showed that a GB score ≥12 and an AIMS65 score ≥2 were significantly associated with rebleeding in the UGIB group, whereas a NOBLADS score ≥4 was significantly associated with rebleeding in the LGIB group. Notably, the influence of emergency endoscopy differed according to GI bleeding location. The clinical course was significantly worse in patients with UGIB than in patients with LGIB. The influence of emergency endoscopy differed according to GI bleeding location.

Sections du résumé

BACKGROUND AND AIM OBJECTIVE
With recent technological advances in the field of endoscopic hemostasis, the prognosis of patients with gastrointestinal (GI) bleeding has improved. However, few studies have reported on the clinical course of patients with GI bleeding. This study aimed to evaluate the differences in clinical outcomes of patients with lower GI bleeding (LGIB) compared with upper GI bleeding (UGIB) and the factors related to their prognosis.
METHODS METHODS
Patients who had undergone emergency endoscopy for GI bleeding were retrospectively reviewed. The severity of GI bleeding was evaluated using the Glasgow-Blatchford (GB), AIMS65, and NOBLADS scores. Patients in whom obvious GI bleeding relapsed and/or iron deficiency anemia persisted after emergency endoscopy were considered to exhibit rebleeding.
RESULTS RESULTS
We reviewed 1697 consecutive patients and divided them into UGIB (1054 patients) and LGIB (643 patients) groups. The proportion of patients with rebleeding was significantly greater in the UGIB group than in the LGIB group; the mortality rate was significantly higher in the UGIB group than in the LGIB group. Multivariate analysis showed that a GB score ≥12 and an AIMS65 score ≥2 were significantly associated with rebleeding in the UGIB group, whereas a NOBLADS score ≥4 was significantly associated with rebleeding in the LGIB group. Notably, the influence of emergency endoscopy differed according to GI bleeding location.
CONCLUSIONS CONCLUSIONS
The clinical course was significantly worse in patients with UGIB than in patients with LGIB. The influence of emergency endoscopy differed according to GI bleeding location.

Identifiants

pubmed: 33202164
doi: 10.1080/00365521.2020.1847316
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-93

Auteurs

Minoru Fujita (M)

Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School General Medical Center, Okayama, Japan.

Noriaki Manabe (N)

Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School General Medical Center, Okayama, Japan.

Takahisa Murao (T)

Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.

Mitsuhiko Suehiro (M)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan.

Tomohiro Tanikawa (T)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan.

Jun Nakamura (J)

Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School General Medical Center, Okayama, Japan.

Shogen Yo (S)

Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.

Shinya Fukushima (S)

Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.

Motoyasu Osawa (M)

Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.

Maki Ayaki (M)

Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School General Medical Center, Okayama, Japan.

Takako Sasai (T)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan.

Hirofumi Kawamoto (H)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan.

Akiko Shiotani (A)

Division of Gastroenterology, Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.

Ken Haruma (K)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, Okayama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH